WDM(600055)

Search documents
北京万东医疗科技股份有限公司 第十届监事会第八次会议决议公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-05-21 23:49
Group 1 - The company held the eighth meeting of the tenth Supervisory Board on May 21, 2025, and approved the adjustment of the 2025 stock option incentive plan, including the list of incentive objects, the number of options granted, and the exercise price [1][3][72] - The meeting was attended by all three supervisors, and the resolutions were passed unanimously [2][4][6] - The company plans to cancel the Supervisory Board and amend the Articles of Association, which will be submitted for shareholder approval [5][7][84] Group 2 - The company announced the resignation of Chairman Hu Ziqiang due to personal reasons, effective immediately, and expressed gratitude for his contributions [10][11] - Ma Chibing was elected as the new Chairman of the Board on May 21, 2025, with a term lasting until the end of the current Board's tenure [12][42] Group 3 - The company will grant 9.6 million stock options to 85 eligible incentive objects, with an exercise price of 15.05 yuan per option, effective from May 21, 2025 [13][14][25] - The initial number of options was adjusted from 10.8 million due to the departure of two incentive objects [76][79] - The stock option incentive plan has undergone necessary approvals and complies with relevant regulations [39][81][82] Group 4 - The company will not set up a Supervisory Board, transferring its responsibilities to the Audit Committee of the Board to enhance governance [84] - The Articles of Association will be revised to reflect this change and other necessary updates [85]
晚间公告丨5月21日这些公告有看头
第一财经· 2025-05-21 14:31
Key Points - Vanke A has signed a supplementary agreement with Shenzhen Metro Group for a loan of up to 4.2 billion yuan, with a pledge of up to 6 billion yuan in shares of its subsidiary, Wanwu Cloud [3] - Heng Rui Pharmaceutical has set the final price for its H-share issuance at 44.05 HKD per share, with plans to list on the Hong Kong Stock Exchange on May 23, 2025 [4] - Wan Dong Medical has elected Ma Chibing as the new chairman after Hu Ziqiang resigned from the position [5] - Tianqi Mould has confirmed that there are no undisclosed significant matters amid ongoing major asset restructuring [6] - Zhejiang Rongtai plans to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - ST Mingcheng intends to publicly transfer 45% of its subsidiary, Time Media, which will no longer be included in the consolidated financial statements [8] - Shanghai Xiba plans to purchase patent assets for 2 million yuan and 500,000 yuan, and establish subsidiaries to promote the commercialization of new technologies [9] - Jushen Co. has received a total of 95.7 million yuan in dividends from its six wholly-owned subsidiaries [10] - ST Asia Pacific has confirmed no undisclosed significant matters or ongoing major plans [11] - Tianrong Tianyu's controlling shareholder's agreement will not be renewed after its expiration [12] - Wangzi New Materials has stated that its energy storage capacitor business is minimal and will not significantly impact its performance [13] - Nanjing Port has clarified that its foreign trade container business does not have direct routes to the U.S. [14] - Jinlongyu has indicated that its solid-state battery business has not yet formed stable long-term revenue [15] - Tianzhihang's subsidiary plans to raise capital by introducing investors [16] - State Grid Information plans to acquire 100% of Yili Technology for 1.853 billion yuan, enhancing its revenue and profit [17] - ST Nongsang will remove its delisting risk warning starting May 23 [18] - Yipin Hong has stated that its innovative drug AR882 has not yet been launched and will not significantly impact recent performance [19] - Huanrui Century has announced a performance compensation plan requiring original shareholders to compensate 116 million shares [20] - Huaren Health plans to acquire stakes in three pharmaceutical chain companies for a total of 3.282 billion yuan [21][22] - Hongming Co. is planning to acquire 83% of Shenzhen Chisu for 1.51 billion yuan [23] - Aishida intends to acquire an additional 7% stake in its subsidiary Qianjiang Robot for 13.09 million yuan [24] - Dasheng Intelligent has signed a contract worth 11.5 million yuan for a high-efficiency machine room project [25] - Jinggu Co. has received a notice to supply wheels for a major global automaker, with expected sales of approximately 158 million USD over ten years [26] - Pingzhi Information has signed a framework agreement with China Mobile for antenna products worth up to 13.01 million yuan [27] - Shanghai Laishi's controlling shareholder plans to increase its stake by 250 million to 500 million yuan [28] - Qixia Construction's shareholder plans to reduce its stake by up to 3% [29] - Sichuan Gold's major shareholders plan to reduce their stakes by up to 5.5% [30] - Qingyun Technology's shareholders plan to reduce their stakes by up to 4.5% [31] - Rhein Biological's directors plan to reduce their stakes by up to 0.14% [32] - Qingmu Technology's shareholder plans to reduce its stake by up to 3% [33] - Sanrenxing's employee shareholding platform plans to reduce its stake by up to 3% [34][35] - Juzhi Technology's director plans to reduce his stake by up to 40,000 shares [36] - Jingwang Electronics' major shareholders plan to reduce their stakes by up to 2.99% [37] - Jujiao Co. plans to reduce its stake by up to 2.6% [38] - Xiyu Tourism's major shareholder plans to reduce its stake by up to 3% [39]
万东医疗: 华泰联合证券有限责任公司关于北京万东医疗科技股份有限公司2025年股票期权激励计划调整及首次授予相关事项之独立财务顾问报告
Zheng Quan Zhi Xing· 2025-05-21 11:42
Core Viewpoint - The report discusses the adjustments and initial grant related to the stock option incentive plan of Beijing Wandong Medical Technology Co., Ltd. for 2025, highlighting the approval process and compliance with relevant regulations [1][2][6]. Summary by Sections Definitions - The report defines key terms such as "incentive plan," "grant date," "exercise price," and "exercise conditions," which are essential for understanding the stock option incentive plan [1]. Approval Process - On March 20, 2025, the company's board of directors approved the draft of the stock option incentive plan and related management measures [3]. - The supervisory board also approved the plan on the same day, confirming the list of incentive objects [4]. - The plan was publicly announced from March 28 to April 8, 2025, with no objections raised by employees [4]. - The annual shareholders' meeting on April 16, 2025, approved the plan, granting the board the authority to manage related matters [4]. Adjustments to the Incentive Plan - On May 21, 2025, the board and supervisory board approved adjustments to the initial grant list, reducing the number of incentive objects from 87 to 85 and the total stock options from 10.8 million to 9.6 million [5][7]. - The exercise price was adjusted from 15.18 yuan to 15.05 yuan following the completion of the 2024 profit distribution [8]. Compliance and Fairness - The independent financial advisor confirmed that the adjustments and grants comply with the relevant regulations and do not harm the interests of shareholders [9][11]. - The report emphasizes that the conditions for granting stock options have been met, and the incentive objects are valid [7][11]. Financial Impact - The financial advisor suggests that the company should account for the costs associated with the stock option plan in accordance with accounting standards, noting potential dilution effects [11]. Conclusion - The independent financial advisor concludes that the adjustments and initial grants of the stock option incentive plan have received necessary approvals and comply with legal requirements, ensuring no detriment to the company or its shareholders [11].
万东医疗: 《信息披露事务管理制度》(2025年第一次修订本)
Zheng Quan Zhi Xing· 2025-05-21 11:27
General Principles - The information disclosure management system is established to standardize the disclosure behavior of Beijing Wandong Medical Technology Co., Ltd., protect the legal rights of the company and its shareholders, and ensure the authenticity, accuracy, completeness, timeliness, and fairness of disclosed information [2][3]. - The term "information" refers to any information that may significantly impact the company's stock price and information required by regulatory authorities [3]. Responsibilities of Disclosure Parties - The board of directors is responsible for leading and managing information disclosure affairs, with the board secretary coordinating and organizing these activities [8][9]. - All directors and senior management are responsible for the content of information disclosures, ensuring that the information is true, accurate, complete, timely, and fair [8][10]. Disclosure Principles and Standards - The company must adhere to the principles of authenticity, timeliness, completeness, accuracy, and fairness in its information disclosures [16][10]. - Information must be disclosed through designated channels and in accordance with strict procedures to ensure reliability and prevent any form of falsification [16]. Reporting Procedures - Regular reports, including annual, semi-annual, and quarterly reports, must be prepared and disclosed within specified timeframes [18][12]. - The company must report and announce significant transactions within two working days if they meet the standards set by the listing rules [20]. Confidentiality Measures - All major information is considered insider information and must be reported and circulated internally according to the established procedures before public disclosure [34][19]. - Individuals with access to insider information are required to maintain confidentiality and are prohibited from disclosing such information before it is officially released [19][20]. Training and Compliance - The board secretary is responsible for organizing training on the information disclosure system for relevant personnel [64]. - The company must ensure compliance with national laws, regulations, and the listing rules regarding information disclosure [27].
万东医疗: 《公司章程》(2025年第二次修订本)
Zheng Quan Zhi Xing· 2025-05-21 11:27
北京万东医疗科技股份有限公司 公司章程 (2025 年第二次修订本) 第一章 总则 第一条 为规范北京万东医疗科技股份有限公司(以下简称"公司")的组织和行 为,维护公司、股东和债权人的合法权益,保护职工合法权益,根据《中华人民共和 国公司法》(以下简称《公司法》)、《中华人民共和国证券法》(以下简称《证券法》)、 《上海证券交易所股票上市规则》(以下简称《上市规则》)及《上市公司章程指引》 和其他有关规定,制订本章程。 公司系依照《公司法》和其他有关规定成立的股份有限公司。 第二条 公司经北京市人民政府办公厅京政办函(1997)60 号文批准,以社会募 集方式设立;于一九九七年五月十二日在北京市工商行政管理局注册登记,取得企业 法人营业执照,统一社会信用代码为 9111000063379674X4。 第三条 公司于一九九七年四月十五日经中国证券监督管理委员会(以下简称"中 国证监会")批准,首次向境内投资人发行的以人民币认购的内资股为 1500 万股,于 一九九七年五月十九日在上海证券交易所上市。 第四条 公司注册名称:北京万东医疗科技股份有限公司 英文名称:Beijing Wandong Medical ...
万东医疗: 《股东会议事规则》(2025年第一次修订本)
Zheng Quan Zhi Xing· 2025-05-21 11:27
北京万东医疗科技股份有限公司 股东会议事规则 (2025 年第一次修订本) 北京万东医疗科技股份有限公司 股东会议事规则 为适应上市公司规范运作,提高股东会议事效率,保障股东合法权益, 保证股东会程序及决议合法性,根据《中华人民共和国公司法》 量处于第一位或者对北京万东医疗科技股份有限公司有实际控制权的股 东。 副总裁、副总裁、董事会秘书、财务负责人、总工程师。 关联人发生的转移资源或义务的事项。 东,或者按照股权比例、公司章程或经营协议,北京万东医疗科技股份有 限公司能够控制其董事会组成的公司。 、《中华人 民共和国证券法》等法律、法规及公司章程的规定,特制定本规则。 释义: 本规则中,除非文义另有所指,下列词语具有如下含义: 主选举产生的,包括由股东代表出任的董事、职工代表出任的董事、在公 司任职的董事和独立董事。 其他形式民主选举产生的于董事会审计委员会任职的董事。 以上的股东。 社会公众股股东在中国证券登记结算有限责任公司上海分公司登记在册 的某一具体日期。 或传真至北京万东医疗科技股份有限公司完成表决,从而形成股东会决 议。 权的过半数通过的决议。 权的三分之二以上通过的决议。 第 1 条 股东会职 ...
万东医疗: 万东医疗监事会关于公司2025年股票期权激励计划首次授予激励对象名单(授予日)的核查意见
Zheng Quan Zhi Xing· 2025-05-21 11:16
北京万东医疗科技股份有限公司 监事会关于公司 2025 年股票期权激励计划首次授予激励对象 名单(授予日)的核查意见 北京万东医疗科技股份有限公司(以下简称"公司")监事会依据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司股权激励管理办法》(以下简 称"《管理办法》")等有关法律、法规及规范性文件和《北京万东医疗科技股 份有限公司章程》(以下简称"《公司章程》")的有关规定,对公司2025年股 票期权激励计划(以下简称"本次激励计划")首次授予激励对象名单(授予日 )进行审核,发表核查意见如下: 一、鉴于公司2名激励对象因离职原因,已不再满足成为公司2025年股票期权 激励对象的条件,所被授予的股票期权予以取消,根据公司 2024年年度股东大会 的授权,公司董事会对本次激励计划的首次授予激励对象名单及授予数量进行相 应调整;鉴于公司2024年年度利润分配已经实施完毕,2025年股票期权激励计划 首次授予的行权价格将相应调整。本次调整后,本次激励计划首次授予激励对象 人数由87人调整为85人,首次授予的股票期权数量由1,080 万份调整为960万份, 行权价格将由15.18元/份调整为15.05元 ...
万东医疗(600055) - 万东医疗2025年股票期权激励计划首次授予激励对象名单
2025-05-21 10:18
一、首次授予激励对象获授股票期权分配情况 注:1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均未 超过公司总股本的 1%。公司全部有效期内的激励计划所涉及的标的股票总数累计不超过股权 激励计划提交股东大会审议时公司股本总额的 10.00%。 北京万东医疗科技股份有限公司 | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1. | 安立群 | 核心骨干人员 | | 2. | 陈超 | 核心骨干人员 | | 3. | 陈健 | 核心骨干人员 | | 4. | 陈林 | 核心骨干人员 | | 5. | 陈杨华 | 核心骨干人员 | | 6. | 崔鸣智 | 核心骨干人员 | | 7. | 董文欣 | 核心骨干人员 | | 8. | 董冶国 | 核心骨干人员 | 2025年股票期权激励计划首次授予激励对象名单 | 姓名 | 职务 | 获授的股票期 权数量(万份) | 占本激励计划拟授出 全部权益数量的比例 | 占授予时股本总额的 比例 | | --- | --- | --- | --- | --- | | 宋金松 | 董事、总裁 | 100 | 9.26% | 0 ...
万东医疗(600055) - 万东医疗关于向2025年股票期权激励计划激励对象首次授予股票期权的公告
2025-05-21 10:18
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法 律责任。 重要内容提示: 根据《上市公司股权激励管理办法》(以下简称"《管理办法》")、 《北京万东医疗科技股份有限公司 2025 年股票期权激励计划(草案)》(以 下简称"本次激励计划"或"激励计划(草案)")等的相关规定,北京 万东医疗科技股份有限公司(以下简称"公司")董事会认为本次激励 计划首次授予条件已经成就。根据公司 2024 年年度股东大会的授权, 公司于 2025 年 5 月 21 日召开第十届董事会第八次会议、第十届监事会第 八次会议,审议通过了《关于向 2025 年股票期权激励计划激励对象首次授 予股票期权的议案》,确定以 2025 年 5 月 21 日为首次授予日,向符合条 件的 85 名激励对象首次授予股票期权 960 万份,行权价格为 15.05 元/ 份。现将有关情况公告如下: 一、本次激励计划已履行的审批程序和信息披露情况 1、2025 年 3 月 20 日,公司召开第十届董事会第六次会议,审议通过 了《关于公司﹤2025 年股票期权激励计划(草案)﹥及其摘 ...
万东医疗(600055) - 万东医疗关于调整2025年股票期权激励计划首次授予激励对象名单、授予数量及行权价格的公告
2025-05-21 10:18
证券代码:600055 证券简称:万东医疗 编号:临 2025-024 北京万东医疗科技股份有限公司 关于调整 2025 年股票期权激励计划首次授予 激励对象名单、授予数量及行权价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法 律责任。 北京万东医疗科技股份有限公司(以下简称"公司")于 2025 年 5 月 21 日召开的第十届董事会第八次会议、第十届监事会第八次会议审议 通过了《关于调整 2025 年股票期权激励计划首次授予激励对象名单、 授予数量以及行权价格的议案》。根据《上市公司股权激励管理办法》(以 下简称"《管理办法》")、公司《2025 年股票期权激励计划(草案)》 (以下简称"本次激励计划"或 "激励计划(草案)")等的相关规定及 公司 2024 年年度股东大会的授权,董事会对公司本次激励计划首次授予 激励对象名单、授予数量以及行权价格进行调整。现将相关调整内容公 告如下: 一、本次激励计划已履行的审批程序和信息披露情况 股票期权的首次授予的激励对象由 87 名变更为 85 名,首次授予的股票期 权数量由 1 ...